Empirical PPI Trial for Heartburn and Abdominal Pain

Rationale for PPI Trial

• The American Gastroenterological Association (AGA) recommends that patients with typical reflux symptoms (heartburn and abdominal pain) without alarm symptoms should receive an empirical trial of single-dose PPI therapy for 4-8 weeks before proceeding to diagnostic testing 1, 3, 4
• Empirical PPI therapy is more cost-effective and safer than immediate endoscopy in low-risk patients 5
• PPI therapy is appropriate when antacids have failed, as antacids provide only temporary symptomatic relief and do not address the underlying acid-related pathology 1, 2

Diagnostic and Therapeutic Approach

• The response to PPI therapy helps confirm acid-related etiology 5
• If symptoms resolve after PPI therapy, wean to the lowest effective dose 1, 2
• If symptoms persist after PPI therapy, increase to twice-daily PPI or switch to a more potent acid suppressive agent 1, 2, 4

Indications for Endoscopy

• Immediate endoscopy is reserved for patients with alarm symptoms (dysphagia, weight loss, bleeding, anemia) 1, 2, 7
• Endoscopy is also indicated for patients who fail to respond to PPI therapy after 4-8 weeks 1, 8, 4

H. pylori Testing

• H. pylori testing is not the next step for patients with heartburn as the predominant symptom, as it suggests GERD rather than peptic ulcer disease 5
• H. pylori testing becomes relevant if PPI therapy fails and endoscopy reveals ulcer disease 5, 6